e-Therapeutics’ (ETX) H118 results were a routine financial update highlighting its continuing focus on partnering the Network-driven Drug Discovery (NDD) platform, out-licensing its NDD-derived preclinical immunoncology (I/O) assets and financial prudence. The H118 operating loss was £2.8m. Cash outflow was £2.0m, resulting in a cash balance of £7.6m at the end of H118. Both R&D and administrative expenses had been reduced from H117.
08 Oct 2018
e-Therapeutics - Keeping the faith
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
e-Therapeutics - Keeping the faith
e-Therapeutics plc (ETX:LON) | 9.1 -0.1 (-12.2%) | Mkt Cap: 53.2m
- Published:
08 Oct 2018 -
Author:
Dr Andy Smith -
Pages:
3
e-Therapeutics’ (ETX) H118 results were a routine financial update highlighting its continuing focus on partnering the Network-driven Drug Discovery (NDD) platform, out-licensing its NDD-derived preclinical immunoncology (I/O) assets and financial prudence. The H118 operating loss was £2.8m. Cash outflow was £2.0m, resulting in a cash balance of £7.6m at the end of H118. Both R&D and administrative expenses had been reduced from H117.